



SPARTHA MEDICAL COMPLETES ITS FIRST ROUND OF FUNDING TO DEVELOP ITS CUSTOMISED COATINGS OFFER

Strasbourg, FRANCE, 8 Decembre 2021. SPARTHA Medical, a French MedTech company specialising in the development of multifunctional antimicrobial, antiviral and anti-inflammatory coatings, is pleased to announce that a finalised fundraising round of **€1.4 million** by Alsace Business Angels, Yeast, WiSEED and BPI (*Banque Publique d'Investissement*, under instruction).

SPARTHA Medical was born out of the discovery of new properties of innovative biomaterials based on natural biopolymers. Inspired by the 300 Spartans who held off an army of 150,000 soldiers, SPARTHA Medical wants to help protect and arm the public with human and environmental friendly formulations to fight all forms of infection.

The company has set up a B2B service platform based on its technology, which consists of natural biopolymers with antiviral, antibacterial and anti-inflammatory properties. This platform offers a complete service ranging from feasibility studies to product co-development, including the improvement of existing products and a very wide range of materials and geometries. The company is also developing two ranges of biocompatible products that will be offered for sale to B2B (antimicrobial and procicatrising medical kit) and B2C (consumer hygiene product).

SPARTHA Medical aims to become the market leader in customised coatings, using a platform supported by artificial intelligence. The company's vision is to be at the forefront of the agile development of future biocompatible, biodegradable/ecological disinfectants and coatings.

This first round of financing has made it possible to unite two networks of business angels from the Grand Est region, as well as WiClub Santé investors, with additional funding from complementary financing organisations and around SPARTHA Medical's project. It will enable the company to pursue its co-development projects in order to establish licensing agreements with industrial players in the medical device sector, as well as to deploy its range of proprietary products by implementing the necessary regulatory clinical trials. At the same time, SPARTHA Medical aims to be ISO 9001 and ISO 13485 certified. Finally, this fundraising will enable the company to consolidate the partnerships already in place with its international clients.

Nihal Engin Vrana, CEO of SPARTHA Medical, **“This round of fundraising is a very important step for us which brings us closer to our goal of being a reference company in the field of multifunctional coatings.”**

Thierry Alliotte, representative of Yeast, **“SPARTHA Medical has developed a completely new antimicrobial control process, which can have considerable applications in the fields of hygiene and the prevention of nosocomial infections in hospitals. YEAST members are very proud to be able to support this promising start-up, and have full confidence in the disruptive potential of the innovation and the entrepreneurial qualities of the founders.”**

Eric Olivier, representative of Alsace Business Angels, **“The three main assets of SPARTHA Medical that attracted us from the first pitch and that were confirmed throughout the appraisal are: an innovative technology, an experienced and close-knit team headed by a leader who is a good listener and a real potential for commercial development in various fields. We are excited to be able to support SPARTHA Medical in its quest to meet the challenges of today and tomorrow.”**

Mathilde Iclanzan, Managing Director of WiSEED, **“With WiCLUB Santé, WiSEED and SEMIA are offering an innovative financing mechanism for companies in the biotech, medtech and e-health sectors. In a health context that we now know is different, SPARTHA offers a customised solution for professionals in the medical world. An innovative and promising project, which has been widely praised by WiSEEDers, and which we are proud to support in its seed phase.”**

Stéphane Chauffriat, Director of SEMIA and Quest for Change: **"SPARTHA Medical is one of the first start-ups to benefit from the WiClub Santé. This innovative financing tool was developed in partnership with WISEED to facilitate seed financing for biotech, medtech and e-health projects supported by Quest for Change. Spartha Medical's fundraising is a concrete example of this strategy and encourages us to multiply this type of initiative, with a new fundraising round underway until December."**

About SPARTHA Medical. Founded in 2019 and based in Strasbourg, SPARTHA Medical is a BioTech/MedTech company at the preclinical stage, resulting from the work of the National Institute of Health and Medical Research (Inserm) U1121 unit, which develops coatings based on natural biopolymers with antimicrobial, antiviral and anti-inflammatory properties. SPARTHA Medical's ambition is to protect medical devices and all types of surfaces from infectious risks by offering multifunctional and easy-to-apply coating solutions. Winner of several awards (i-Lab 2019, Bourse Frenchtech Emergence, Fond'Action Alsace) and invested in several international development programmes (NETVA, Innouvo, EIC InvestHorizon Accelerator), SPARTHA Medical has been named one of the "100 startups to invest in in 2021" by Challenges magazine. SPARTHA Medical is incubated within SEMIA, is a member of Biovalley France and was part of a maturation project supported by the TTO SATT Conectus.

About Alsace Business Angels. Created in 2006, Alsace Business Angels is a regional association aiming to develop investments in the local economy and to support innovative entrepreneurs. Alsace BA invests and gets involved! Their support takes the form of financing, but also of a benevolent accompaniment in the form of sharing experience, skills and networks. For more information www.alsacebusinessangels.com.

About WiClub Santé. WISEED, an independent player and historical leader in the crowdfunding industry, and SEMIA, a member of the "Quest for Change" network of incubators of excellence in the Grand Est region, have launched an innovative financing tool in March 2021 for Biotech, Medtech and e-Health projects supported by the Grand Est health innovation ecosystem. Through a single subscription to WiClub Santé, investors gain access to a selection of candidates from SEMIA's portfolio of healthcare start-ups, submitted to WISEED's commitment committee and audited by its analysts. The investments are eligible for tax reduction mechanisms (25%) and tax exemption in the form of a contribution-assignment. At the end of the first financing round (March to July), more than €700,000 was raised and invested in three of SEMIA's high potential start-ups, including Spartha Medical.

About Yeast. Yeast is a club of 23 business angels (BAN) interested in high-potential projects in the Grand Est and Luxembourg. Yeast was created in early 2014 in Lorraine, by successful regional entrepreneurs willing to share their expertise and advice with regional startups. Yeast has made 36 investments in 6 years, in 28 startups, for a total of €3.5M (€24M with leverage). Yeast is a member of France Angels and co-founder of Est Angels. More information: www.yeast.fr | Contact: Boris Ouarnier (06.27.59.23.71 / contact@yeast.fr)

CONTACT

Dr. Nihal Engin Vrana, CEO
contact@sparthamedical.eu

www.sparthamedical.eu

@sparthamedical



The invisible shields.